News
MANE
63.15
+3.78%
2.30
Veradermics (VDPHL01): Accelerating Hair Loss Outcomes and Social Listening Insights Support Buy/High-Risk Rating and $85 Target
TipRanks · 1d ago
Tango Therapeutics is the best performing healthcare stock in March
Seeking Alpha · 1d ago
Veradermics Stock Falls 8% After Reporting Wider Loss In Q4, FY25
NASDAQ · 1d ago
Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate
Benzinga · 1d ago
Veradermics reports Q4 results
Seeking Alpha · 2d ago
Veradermics reports Q4 net loss $21.8M vs $5.7M last year
TipRanks · 2d ago
*Veradermics: Runway To Support Current Operating Plans Into 2029 >MANE
Dow Jones · 2d ago
Press Release: Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Dow Jones · 2d ago
*Veradermics 4Q Loss $21.8M >MANE
Dow Jones · 2d ago
Press Release: Veradermics Reports Fourth Quarter -2-
Dow Jones · 2d ago
Weekly Report: what happened at MANE last week (0323-0327)?
Weekly Report · 2d ago
Veradermics management to meet with Jefferies
TipRanks · 03/24 18:40
Weekly Report: what happened at MANE last week (0316-0320)?
Weekly Report · 03/23 10:42
Senior Living REIT IPO Shows Wall Street Remains Hot for Yield Plays
Barron‘s · 03/20 18:00
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
Barchart · 03/18 06:00
Weekly Report: what happened at MANE last week (0309-0313)?
Weekly Report · 03/16 10:42
Weekly Report: what happened at MANE last week (0302-0306)?
Weekly Report · 03/09 10:42
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals
Simply Wall St · 03/05 11:41
Veradermics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 03/02 19:00
More
Webull provides a variety of real-time MANE stock news. You can receive the latest news about VERADERMICS INC through multiple platforms. This information may help you make smarter investment decisions.
About MANE
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.